PET imaging of new target CDK19 in prostate cancer.

[1]  Xinrui Shi,et al.  Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer , 2022, Cell & bioscience.

[2]  Joel Vargas Ahumada,et al.  Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation , 2022, Diagnostics.

[3]  M. Sydes,et al.  Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. , 2022, European urology.

[4]  M. Rubin,et al.  Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies , 2022, The Journal of pathology.

[5]  A. Maes,et al.  mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis , 2022, The Journal of Nuclear Medicine.

[6]  Yong-ping Su,et al.  CDK19 regulates the proliferation of hematopoietic stem cells and acute myeloid leukemia cells by suppressing p53-mediated transcription of p21 , 2022, Leukemia.

[7]  G. Tinoco,et al.  Primary Intranodal Epithelioid Hemangioendothelioma with Molecular Confirmation , 2022, International journal of surgical pathology.

[8]  John F. Trant,et al.  Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells , 2022, Proceedings of the National Academy of Sciences.

[9]  C. Rudin,et al.  Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3 , 2022, The Journal of Nuclear Medicine.

[10]  F. Bray,et al.  Epidemiology and Prevention of Prostate Cancer. , 2021, European urology oncology.

[11]  Hanqi Lei,et al.  MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer , 2021, Computational and structural biotechnology journal.

[12]  John F. Ouyang,et al.  The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology , 2021, Nature Communications.

[13]  Chan Hyuk Kim,et al.  A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand , 2021, Science Advances.

[14]  S. Perner,et al.  CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. , 2021, Human Pathology.

[15]  P. Nelson,et al.  Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer , 2021, JCI insight.

[16]  S. Fanti,et al.  Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer , 2021, The Journal of Nuclear Medicine.

[17]  Yu Zhao,et al.  Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine , 2020, Molecular cancer.

[18]  M. Webb,et al.  An exceptional response to 177LuPSMA undermined by neuroendocrine transformation , 2020, Urology case reports.

[19]  C. Stief,et al.  First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients , 2020, The Journal of Nuclear Medicine.

[20]  F. Zattoni,et al.  PET/MRI in prostate cancer: a systematic review and meta-analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[22]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[23]  R. Kuefer,et al.  Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer , 2020, International journal of cancer.

[24]  A. Wutz,et al.  Cdk8 is required for establishment of H3K27me3 and gene repression by Xist and mouse development , 2020, Development.

[25]  G. Superti-Furga,et al.  Transcriptional Responses to IFN-γ Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions. , 2019, Molecular cell.

[26]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[27]  Z. Savin,et al.  Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard , 2019, The Journal of Nuclear Medicine.

[28]  N. Jiang,et al.  Enhancing Prostate‐Cancer‐Specific MRI by Genetic Amplified Nanoparticle Tumor Homing , 2019, Advanced materials.

[29]  Sangdun Choi,et al.  A Structure-Based Drug Discovery Paradigm , 2019, International journal of molecular sciences.

[30]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[31]  Nicola J. Rinaldi,et al.  An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells , 2019, Genome research.

[32]  D. Taatjes,et al.  Regulatory functions of the Mediator kinases CDK8 and CDK19 , 2018, Transcription.

[33]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[34]  Michael L. Gatza,et al.  Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer , 2018, Oncogene.

[35]  A. Zoubeidi,et al.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer , 2018, Nature Reviews Urology.

[36]  S. Fine.  Neuroendocrine tumors of the prostate , 2018, Modern Pathology.

[37]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[38]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[39]  S. Armstrong,et al.  Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.

[40]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[41]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[42]  M. Ittmann,et al.  Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression , 2011, PloS one.